5 Stocks On Investors’ Radar After Earnings Reports

In this article, we discuss the 5 stocks on investors’ radar after earnings reports. If you want to read our detailed analysis of these companies, go directly to the 10 Stocks On Investors’ Radar After Earnings Reports. 

5. DuPont de Nemours, Inc. (NYSE:DD)

Number of Hedge Fund Holders: 51

Shares of DuPont de Nemours, Inc. (NYSE:DD) rose over six percent on Tuesday, February 8, 2022, after delivering impressive profit and sales for the fourth quarter. The company reported adjusted earnings of $1.08 per share, up 54 percent versus last year.

Revenue for the quarter also surged 14 percent on a year-over-year basis to $4.3 billion. Analysts were expecting DuPont de Nemours, Inc. (NYSE:DD) to post earnings of 99 cents per share on revenue of $4.03 billion.

DuPont de Nemours, Inc. (NYSE:DD) also released its segment-wise sales performance. Its electronics and industrial revenue jumped 19 percent to $1.5 billion, water and protection revenue advanced 16 percent to $1.4 billion and mobility and materials revenue increased 12 percent to $1.3 billion in the quarter.

Looking forward, DuPont de Nemours, Inc. (NYSE:DD) expects adjusted earnings in the range of $4.60 – $4.90 per share and revenue between $17.4 – $17.8 billion for the current fiscal year.

Discussing the results, CEO Ed Breen said in a statement:

“Sustained strong demand in key end-markets such as electronics and water, along with our continued ability to offset raw material inflation with price, were critical to our fourth quarter results.”

4. Amgen Inc. (NASDAQ:AMGN)

Number of Hedge Fund Holders: 52

Shares of Amgen Inc. (NASDAQ:AMGN) climbed to a nearly six-month high on Tuesday, February 8, 2022, after announcing a better-than-expected profit for the fourth quarter. The California-based biopharmaceutical company earned $4.36 per share on an adjusted basis, topping estimates of $4.04 per share.

On the downside, Amgen Inc. (NASDAQ:AMGN) generated revenue of $6.85 billion, slightly below analysts’ average estimate of $6.87 billion. The latest quarterly revenue was mainly driven by its Covid-19 manufacturing partnership with Eli Lilly.

Amgen Inc. (NASDAQ:AMGN) also updated its sales outlook for 2022. It expects revenue in the range of $25.4 – $26.5 billion for the current year. This compares to analysts’ average estimate of $27 billion.

Speaking on the results, CEO Robert Bradway said:

“We realized strong volume growth for many of our key products during last year. These products, combined with our many pipeline opportunities, position us well for long-term growth.”

3. Peloton Interactive, Inc. (NASDAQ:PTON)

Number of Hedge Fund Holders: 62

Peloton Interactive, Inc. (NASDAQ:PTON) recently announced weak financial results for its fiscal second quarter. However, its shares jumped over 25 percent on Tuesday, February 8, 2022, despite the disappointing performance. Many attributed the latest surge to rumors that e-commerce giant Amazon and sportswear company Nike might be interested in buying Peloton.

Coming back to the latest financial results, Peloton Interactive, Inc. (NASDAQ:PTON) posted a loss of $1.39 per share, compared to earnings of 18 cents per share in the year-ago period. Revenue for the quarter increased 6 percent on a year-over-year basis to $1.13 billion. Analysts were looking for a loss of $1.20 per share on revenue of $1.15 billion.

If we look at the important growth drivers, the company’s connected fitness subscribers climbed 66 percent to 2.77 million in the quarter, while total members increased to more than 6.6 million. In addition, Peloton Interactive, Inc. (NASDAQ:PTON) reported that its paid digital subscribers jumped 28 percent versus last year to 862,000 in the quarter.

Among other updates, Peloton Interactive, Inc. (NASDAQ:PTON) announced that CEO John Foley would be replaced by former Spotify’s CFO, Barry McCarthy. The company also announced plans of trimming nearly 2,800 jobs worldwide amid weak demand for its products.

2. Fiserv, Inc. (NASDAQ:FISV)

Number of Hedge Fund Holders: 65

Shares of Fiserv, Inc. (NASDAQ:FISV) turned red on Tuesday, February 8, 2022, after announcing mixed financial results for the fourth quarter. The Wisconsin-based fintech company reported adjusted earnings of $1.57 per share, up 21 percent on a year-over-year basis.

In addition, Fiserv, Inc. (NASDAQ:FISV) posted an adjusted revenue of $4.02 billion, compared to $3.62 billion for the comparable period of 2020. Analysts had projected earnings of $1.56 and revenue of $4.03 billion.

Fiserv, Inc. (NASDAQ:FISV) also released its financial outlook for 2022. It expects adjusted earnings in the range of $6.40 – $6.55 per share and organic revenue growth between 7 – 9 percent for the current year.

Discussing the results, CEO Frank Bisignano said:

“For 2021, Fiserv had another successful year of delivering on our growth agenda – attaining the high end of our original organic revenue growth outlook and coming in well above our original adjusted EPS outlook, all while investing in the business to fuel further growth as we innovate to provide value for our clients.”

1. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 74

Pfizer Inc. (NYSE:PFE) recently announced a better-than-expected profit for the fourth quarter. However, its quarterly sales fell below expectations, sending its shares down nearly three percent on Tuesday, February 8, 2022.

The New York-based pharmaceutical giant earned $1.08 per share on an adjusted basis, representing a surge of more than two folds versus the year-ago period. It also crushed the consensus forecast of 87 cents per share.

Revenue for the quarter also skyrocketed 105 percent on a year-over-year basis to $23.84 billion, mainly driven by sales of its coronavirus vaccine. However, analysts were expecting Pfizer Inc. (NYSE:PFE) to generate revenue of $24.16 billion

Looking forward, Pfizer Inc. (NYSE:PFE) expects adjusted earnings in the range of $6.35 – $6.55 per share and revenue between $98 – $102 billion for 2022. But the outlook fell short of analysts’ average estimate of $6.71 per share for earnings and $103.2 billion for revenue.

Speaking on the results, CFO of Pfizer Inc. (NYSE:PFE), Frank D’Amelio,, said in a statement:

“As I prepare to retire as CFO of Pfizer, I am proud to see that the company is performing better than at any other time during my nearly 15 years here. Today we are issuing guidance for the coming year which, if achieved, would represent the highest level of annual revenues and Adjusted diluted EPS in Pfizer’s long history.”

You can also take a peek at Early Retirement Portfolio: 15 Stocks to Live Off Dividends and Top 10 Stock Picks of Thomas Bancroft’s Makaira Partners.

Follow Insider Monkey on Twitter